Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy.

Dimick SM, Sallee B, Asztalos BF, Pritchard PH, Frohlich J, Schaefer EJ.

J Clin Lipidol. 2014 Mar-Apr;8(2):223-30. doi: 10.1016/j.jacl.2013.11.005. Epub 2013 Dec 11.

PMID:
24636183
2.

Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.

Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN.

Breast Cancer Res Treat. 2012 Dec;136(3):769-76. doi: 10.1007/s10549-012-2294-z. Epub 2012 Oct 23.

PMID:
23089983
3.

Low accessibility and chemical activity of PAHs restrict bioremediation and risk of exposure in a manufactured gas plant soil.

Reichenberg F, Karlson UG, Gustafsson O, Long SM, Pritchard PH, Mayer P.

Environ Pollut. 2010 May;158(5):1214-20. doi: 10.1016/j.envpol.2010.01.031. Epub 2010 Mar 3.

PMID:
20202727
4.

Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia.

Vissers MN, Trip MD, Pritchard PH, Tam P, Lukic T, de Sain-van der Velden MG, de Barse M, Kastelein JJ.

Eur J Clin Pharmacol. 2008 Jul;64(7):651-61. doi: 10.1007/s00228-008-0462-1. Epub 2008 Mar 5.

5.

Structural differences between wild-type and fish eye disease mutant of lecithin:cholesterol acyltransferase.

Reshetnyak Y, Tchedre KT, Nair MP, Pritchard PH, Lacko AG.

J Biomol Struct Dyn. 2006 Aug;24(1):75-82.

PMID:
16780378
6.

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA.

Ann Oncol. 2005 May;16(5):707-15. Epub 2005 Apr 7.

PMID:
15817595
7.

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.

van Raalte DH, Li M, Pritchard PH, Wasan KM.

Pharm Res. 2004 Sep;21(9):1531-8. Review.

PMID:
15497675
8.

Development and characterization of liposomal disodium ascorbyl phytostanyl phosphates (FM-VP4).

Ng AW, Lukic T, Pritchard PH, Wasan KM.

Drug Dev Ind Pharm. 2004 Aug;30(7):739-58.

PMID:
15491052
9.
10.
11.

Elucidating the microbial component of natural attenuation.

Smets BF, Pritchard PH.

Curr Opin Biotechnol. 2003 Jun;14(3):283-8. Review.

PMID:
12849781
12.

Effects of disodium ascorbyl phytostanol phosphates (FM-VP4) on cholesterol accumulation within rat intestinal cells.

Wasan KM, Yau E, Boulanger KD, Ramswamy M, Pritchard PH.

AAPS PharmSci. 2003;5(1):E6.

13.
15.

A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data.

Lear SA, Ignaszewski A, Linden W, Brozic A, Kiess M, Spinelli JJ, Pritchard PH, Frohlich JJ.

Curr Control Trials Cardiovasc Med. 2002 Nov 12;3(1):9.

16.

Effect of cyclosporine A on the binding affinity and internalization of low-density lipoproteins in human skin fibroblasts.

Wasan KM, Donnachie EM, Seccombe DW, Pritchard PH.

J Pharm Sci. 2002 Dec;91(12):2520-4.

PMID:
12434395
17.
18.

Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells.

Ramaswamy M, Yau E, Wasan KM, Boulanger KD, Li M, Pritchard PH.

J Pharm Pharm Sci. 2002 Jan-Apr;5(1):29-38.

19.

Extensive lifestyle management intervention following cardiac rehabilitation: pilot study.

Lear SA, Ignaszewski A, Laquer EA, Pritchard PH, Frohlich JJ.

Rehabil Nurs. 2001 Nov-Dec;26(6):227-32.

PMID:
12035723
20.
21.

Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils.

Wasan KM, Najafi S, Peteherych KD, Pritchard PH.

J Pharm Sci. 2001 Nov;90(11):1795-9.

PMID:
11745737
24.

Overexpression of acyl-coA binding protein and its effects on the flux of free fatty acids in McA-RH 7777 cells.

Yang Y, Pritchard PH, Bhuiyan J, Seccombe DW, Moghadasian MH.

Lipids. 2001 Jun;36(6):595-600.

PMID:
11485163
25.

Probing the 121-136 domain of lecithin:cholesterol acyltransferase using antibodies.

Murray KR, Nair MP, Ayyobi AF, Hill JS, Pritchard PH, Lacko AG.

Arch Biochem Biophys. 2001 Jan 15;385(2):267-75.

PMID:
11368007
26.

Assessing plasma pharmacokinetics of cholesterol following oral coadministration with a novel vegetable stanol mixture to fasting rats.

Wasan KM, Holtorf L, Subramanian R, Cassidy SM, Pritchard PH, Stewart DJ, Novak E, Moghadasian MH.

J Pharm Sci. 2001 Jan;90(1):23-8.

PMID:
11064375
28.

Biochemical and compositional analyses of recombinant lecithin:cholesterol acyltransferase (LCAT) obtained from a hepatic source.

Ayyobi AF, Lacko AG, Murray K, Nair M, Li M, Molhuizen HO, Pritchard PH.

Biochim Biophys Acta. 2000 Feb 24;1484(1):1-13.

PMID:
10685026
29.

Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux.

Daum U, Langer C, Duverger N, Emmanuel F, Benoit P, Denèfle P, Chirazi A, Cullen P, Pritchard PH, Bruckert E, Assmann G, von Eckardstein A.

J Mol Med (Berl). 1999 Aug;77(8):614-22.

PMID:
10543393
30.

Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Wasan KM, Subramanian R, Chou JW, Ramaswamy M, Pritchard PH.

Pharm Res. 1999 Jul;16(7):1067-73.

PMID:
10450932
31.

A first British case of fish-eye disease presenting at age 75 years: a double heterozygote for defined and new mutations affecting LCAT structure and expression.

Winder AF, Owen JS, Pritchard PH, Lloyd-Jones D, Vallance DT, White P, Wray R.

J Clin Pathol. 1999 Mar;52(3):228-30.

32.

Separation of liposomes from plasma components using fast protein liquid chromatography.

Choice E, Ayyobi AF, Pritchard PH, Madden TD.

Anal Biochem. 1999 May 15;270(1):1-8.

PMID:
10328758
33.

Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers.

Daum U, Leren TP, Langer C, Chirazi A, Cullen P, Pritchard PH, Assmann G, von Eckardstein A.

J Lipid Res. 1999 Mar;40(3):486-94.

34.
35.

Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband.

Argyropoulos G, Jenkins A, Klein RL, Lyons T, Wagenhorst B, St Armand J, Marcovina SM, Albers JJ, Pritchard PH, Garvey WT.

J Lipid Res. 1998 Sep;39(9):1870-6.

36.
37.

Characterization of recombinant human plasma lecithin: cholesterol acyltransferase (LCAT): N-linked carbohydrate structures and catalytic properties.

Lacko AG, Reason AJ, Nuckolls C, Kudchodkar BJ, Nair MP, Sundarrajan G, Pritchard PH, Morris HR, Dell A.

J Lipid Res. 1998 Apr;39(4):807-20.

38.
39.

Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles.

Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ.

Biochim Biophys Acta. 1998 Jan 19;1368(2):306-20.

40.

Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ.

Pharm Res. 1997 Nov;14(11):1613-20.

PMID:
9434283
41.

Purification of recombinant lecithin: cholesterol acyltransferase.

Nair MP, Kudchodkar BJ, Pritchard PH, Lacko AG.

Protein Expr Purif. 1997 Jun;10(1):38-41.

PMID:
9179288
42.

Phylogenetic and physiological comparisons of PAH-degrading bacteria from geographically diverse soils.

Mueller JG, Devereux R, Santavy DL, Lantz SE, Willis SG, Pritchard PH.

Antonie Van Leeuwenhoek. 1997 May;71(4):329-43.

PMID:
9195008
43.

Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels.

Kuivenhoven JA, de Knijff P, Boer JM, Smalheer HA, Botma GJ, Seidell JC, Kastelein JJ, Pritchard PH.

Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):560-8.

PMID:
9102177
44.

"Tall oil"-derived phytosterols reduce atherosclerosis in ApoE-deficient mice.

Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ.

Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):119-26.

PMID:
9012646
45.

Kinetics of chromate reduction during naphthalene degradation in a mixed culture.

Shen H, Pritchard PH, Sewell GW.

Biotechnol Bioeng. 1996 Nov 5;52(3):357-63.

PMID:
18629905
46.

An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).

Kuivenhoven JA, Weibusch H, Pritchard PH, Funke H, Benne R, Assmann G, Kastelein JJ.

J Clin Invest. 1996 Jul 15;98(2):358-64.

47.

Two novel molecular defects in the LCAT gene are associated with fish eye disease.

Kuivenhoven JA, Stalenhoef AF, Hill JS, Demacker PN, Errami A, Kastelein JJ, Pritchard PH.

Arterioscler Thromb Vasc Biol. 1996 Feb;16(2):294-303. Review.

PMID:
8620346
48.

A unique genetic and biochemical presentation of fish-eye disease.

Kuivenhoven JA, van Voorst tot Voorst EJ, Wiebusch H, Marcovina SM, Funke H, Assmann G, Pritchard PH, Kastelein JJ.

J Clin Invest. 1995 Dec;96(6):2783-91.

49.

Effects of high-fat diet and fasting on levels of acyl-coenzyme A binding protein in liver, kidney, and heart of rat.

Bhuiyan J, Pritchard PH, Pande SV, Seccombe DW.

Metabolism. 1995 Sep;44(9):1185-9.

PMID:
7666793
50.

Effect of interfacial pressure on the binding and phospholipase A2 activity of recombinant human lecithin-cholesterol acyltransferase.

Weinberg RB, Jones JB, Pritchard PH, Lacko AG.

Biochem Biophys Res Commun. 1995 Jun 26;211(3):840-6.

PMID:
7598713

Supplemental Content

Loading ...
Support Center